Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515846 | 1.00 | HTR1B (0.49) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL25515853 | 1.00 | HTR1B (0.49) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL25515896 | 0.86 | ALOX15 (0.37) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL25515989 | 0.86 | ALOX15 (0.37) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL25516065 | 0.86 | ALOX15 (0.37) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL25516089 | 0.79 | ALOX15 (0.43) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL25516103 | 0.79 | ALOX15 (0.43) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL25516115 | 0.79 | ALOX15 (0.43) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL25533176 | 0.77 | SIGMAR1 (0.46) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL25533321 | 0.77 | SIGMAR1 (0.46) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150965-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150965-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | DBH, PNMT, MBTD1 | HTR1B 50/4885SLC6A4 205/4885SLC6A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.